INTEGRATED BIOPHARMA INC (INBP)
D
Pipeline Grade
Financial Position (from SEC Filings)
$5.8M
Cash & Equivalents
$2.4M
Quarterly Burn Rate
$5M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2027-02-01 | Phase2 Readout | — |
Active Clinical Trials (3)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT04136002 | Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode | OTHER | Active Not Recruiting | 44,467 |
| NCT06824194 | Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age | PHASE3 | Active Not Recruiting | 2,360 |
| NCT06972446 | A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis | PHASE2 | Recruiting | 180 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.